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Abstract
Aim: Placental growth hormone (PGH) is a major growth hormone in pregnancy and acts with Insulin Like Growth Factor I
(IGF-I) and Insulin Like Growth Hormone Binding Protein 3 (IGFBP3). The aim of this study was to investigate PGH, IGF-I and
IGFBP3 in non-diabetic (ND) compared to Type 1 Diabetic (T1DM) pregnancies.
Methods: This is a prospective study. Maternal samples were obtained from 25 ND and 25 T1DM mothers at 36 weeks
gestation. Cord blood was obtained after delivery. PGH, IGF-I and IGFBP3 were measured using ELISA.
Results: There was no difference in delivery type, gender of infants or birth weight between groups. In T1DM, maternal PGH
significantly correlated with ultrasound estimated fetal weight (r=0.4, p=0.02), birth weight (r=0.51, p,0.05) and birth
weight centile (r=0.41, p=0.03) PGH did not correlate with HbA1c. Maternal IGF-I was lower in T1DM (p=0.03). Maternal
and fetal serum IGFBP3 was higher in T1DM. Maternal third trimester T1DM serum had a significant band at 16 kD on
western blot, which was not present in ND.
Conclusion: Maternal T1DM PGH correlated with both antenatal fetal weight and birth weight, suggesting a significant role
for PGH in growth in diabetic pregnancy. IGFBP3 is significantly increased in maternal and fetal serum in T1DM
pregnancies compared to ND controls, which was explained by increased proteolysis in maternal but not fetal serum. These
results suggest that the normal PGH-IGF-I-IGFBP3 axis in pregnancy is abnormal in T1DM pregnancies, which are at higher
risk of macrosomia.
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Introduction
Type 1 Diabetes (T1DM) affects less than 1% of the obstetric
population but is a significant cause of fetal and neonatal morbidity
andmortality[1–3].Manyofthesecomplicationsarerelated to fetal
macrosomia [4] that, despite enhancements in glycaemic control, is
still common in diabetic pregnancies [4,5].Macrosomia is related to
an increased risk of unexplained in-utero death, instrumental
delivery, shoulder dystocia and later life obesity [6–8].
Fetal growth is a complex process influenced by genetics,
maternal factors, uterine environment and maternal and fetal
hormones [4,9]. Diabetic mothers have an additional influence of
maternal hyperglycaemia or fluctuating glucose. Differences in
HbA1c may explain 6–23% of differences in birth weight [7].
Additionally, the influence of growth factors, both maternal and
fetal, may be of importance [4].
Human Placental Growth Hormone (PGH) which is secreted by
the syncytiotrophoblast [10] Is found in the maternal circulation
from the sixth week of gestation [11] and gradually replaces
pituitary growth hormone during pregnancy. PGH, also known as
growth hormone variant (GHV) was traditionally thought to be
found only in maternal blood and to influence fetal growth by
regulating maternal supply of nutrients to the fetus via the placenta
[11]. The effect of PGH on fetal growth may be mediated by a
direct autocrine and paracrine mechanisms or via regulation
of Insulin Growth Factor 1 (IGF-I) [12]. As in non-diabetic
pregnancies, there is a positive correlation between maternal PGH
and birth weight in women with diabetics [12]. However, no
studies to date have demonstrated higher levels of total serum
maternal PGH in diabetic pregnancies, despite the higher
incidence of macrosomia in the infants of diabetic mothers. In
one study the mean level of free PGH were significantly higher in
pregnant women with Type 1 Diabetes (T1DM), possibly
associated with the fall in growth hormone binding protein [13].
In the placenta itself, the ratio of PGH to chorionic sommato-
trophin L (CS-L) mRNA is raised compared to non diabetic term
placenta [14]. Both suggest that increased PGH levels drive
increased glucose levels and increased insulin resistance.
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both mitogenic and anabolic actions [15]. The biological actions
of the IGFs are regulated at the level of bioavailability through
association with a family of specific high affinity binding proteins,
termed the IGF binding proteins (IGFBPs). The ligand binding
affinity of the IGFBPs can be modulated by phosphorylation and
proteolysis.
IGF-I is decreased in maternal serum in diabetic pregnancies
compared to non-diabetic controls [16]. Cord serum of IGF1 is
increased in infants of insulin treated mothers (T1DM and T2DM)
compared to non diabetic controls [17].
Insulin like growth factor 3 (IGFBP3) is the predominant
maternal serum IGF binding protein at term. IGFBP3 is the most
abundant binding protein in human adult serum, with a high
affinity for IGF, binding up to 70–80% of total serum IFG-I and
IGF-II [18]. Bound IGF is unable to cross the endothelium into
tissues and therefore IGFBP/IGF complexes act as a reservoir of
circulating IGF, increasing the half-life from 10 minutes to 12–
15 hours [19]. Cord IGFBP3 is higher in infants of T1 and T2
diabetic mothers compared to non-diabetic controls [16].
The aim of this study was to measure the PGH-IGF-I-IGFBP3
axis in non-diabetic (ND) and T1DM pregnancy. In particular, we
hypothesised that fetal PGH would differ between diabetic and
control pregnancies. Additionally we aimed to map in detail the
inter-relationship between maternal and fetal PGH and IGF in
T1DM pregnancy.
Results
Study Groups
25 non-diabetic and 25 T1DM women consented to participate;
matching maternal and cord samples were obtained. There were
no differences between the groups regarding maternal age, parity,
type of delivery or birth weight. Although there was no difference
in crude birth weight measurements, women with T!DM delivered
at an earlier gestational age and the birth weight centile (correcting
birth weight for gestational age at delivery) was higher in the
T1DM group compared to the non-diabetic group T1DM
participants were also more likely to deliver an infant, requiring
admission to the neonatal intensive care or with a poorer
composite perinatal outcome (see Table 1).
Twelve participants (48%) with T1DM had an early HbA1c less
than 7%. Birth weight centile correlated with maternal HbA1c at
14 weeks (r=0.48, p=0.016) and at 36 weeks gestation (r=0.39,
p=0.04).
Maternal and Fetal Growth Factors (Figure 1)
There was no significant difference in maternal or fetal PGH
between non-diabetic and T1DM pregnancies, (Table 2). Mater-
nal IGF-I was lower in T1DM mothers compared with non-
diabetic controls. There was no difference in fetal IGF-I between
infants of diabetic mothers compared with infants of non-diabetic
controls. Maternal IGFBP3 was significantly higher in both
T1DM mothers compared with non-diabetic controls and fetal
serum of infants of diabetic mothers compared with infants of non-
diabetic controls.
Correlation between growth factors
In ND and T1DM combined, there was a significant positive
correlation between maternal and fetal PGH (r=0.28, p=0.04);
there was no other significant correlations between any of the
other maternal and fetal growth factors. There was no correlation
between growth factors in the non-diabetic group alone. In the
T1DM group there was a positive correlation between maternal
IGF-I and fetal PGH (p=0.02). In addition, maternal IGFBP3
positively correlated to both maternal PGH (0.61, p=0.001) and
fetal PGH (0.44, p=0.02).
Correlation between growth factors and birth weight
In the total group there were no direct correlations between any
of the growth factors and birth weight or birth weight centile.
Amongst controls alone no significant correlations or differences
were found between growth factors and birth weight/birth weight
centile. In the diabetic group alone, maternal PGH positively
correlated to birth weight (0.42, p=0.02), and to birth weight
Table 1. Background characteristics of participants.
Non Diabetic n=25 T1DM n=25 p value
Age (years) 32 (22–42) 33 (26–39) 0.64
Parity (% primiparous) 9/25 11/25 0.53
BMI 23.9 (18.7–31.2) 27.3 (21.8–35) 0.01
Mode of Delivery (%Caesarean Section) 20/25 (80%) 21/25 (84%) 0.65
Gender of infant (% female) 10/25 (40%) 16/25 (64%) 0.1
Apgars .7a t1 25/25 23/25 NS
Apgars .7a t5 25/25 25/25 NS
Birth Weight (grammes) 3530 (2715–4230) 3537.5 (2830–4250) 0.16
Gestational Age (weeks) at delivery 39 (37–41) 38 (35–40) 0.01sq
Birth Weight Centile 75 (3–95) 90 (25–100) 0.007
Placental weight 588 (452–705) 580 (398–755) 0.9
Admission to NICU* 0/25 (0%) 9/25 0.001
Composite poor outcome (%)* 0/25 (0%) 7/25 (28%) 0.01
T1DM: Type 1 Diabetes Mellitus. BMI: body mass index. Composite poor outcome included Apgar scores less than 7 at 5 minutes, cord pH less than 7.2 or admission to
neonatal intensive care for an indication other than hypoglycaemia.
*Admission to NICU (neonatal intensive care) for any reason. Data for BMI, Birth Weight, Gestational age at delivery, Birth Weight Centile and Placental Weight presented
as median (range).
doi:10.1371/journal.pone.0029164.t001
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with birth weight.
Glycaemia (Diabetic group alone)
Regarding maternal glycaemia (as measured by maternal HbA1c),
there was no significant correlation between maternal or cord PGH,
IGF-I or IGFBP3 with HbA1c measured in early pregnancy, 14
weeks gestational age (GA), 20 weeks GA or 36 weeks GA.
Comparison was made between levels of PGH, IGF-I and
IGFBP3 based on HbA1c more or less than 7% in the three
trimesters; fetal IGF-I was higher in women with HbA1c greater
than 7% (n=14) in early pregnancy compared with those with a
low early pregnancy HbA1c (n=11) (1.08 ng/ml (0.5–5.2 ng/ml),
vs. 0.4 ng/ml (0.09–1.6 ng/ml) p=0.01). There was no difference
in fetal IGF-I at any other time in pregnancy based on
HbA1c.7%.
Figure 1. Maternal and Fetal placental growth hormone, IGF-I, and IGFBP3 in non diabetic and Type 1 diabetic pregnancy.
doi:10.1371/journal.pone.0029164.g001
IGF Axis in Diabetic Pregnancy
PLoS ONE | www.plosone.org 3 February 2012 | Volume 7 | Issue 2 | e29164There was no difference in other growth factors based on
HbA1c less than and equal to/more than 7% in first, second or
third trimesters. There was no difference in birth weights in
women with HbA1c ./,7% in any trimester.
In comparing levels of PGH, IGF-I and IGFBP3 based on
HbA1c more or less than median for that trimester, fetal IGF-I
was also higher in women with an HbA1c more than median in
both early pregnancy and 14 weeks gestational age. (Early pregnancy
IGF-I in cord blood 0.52 ng/ml (0.09–1.6 ng/ml) in women with
HbA1c less than median vs. 1.17 (0.5–5.2 ng/ml) p=0.01; 14
weeks GA IGF-I cord 0.61 ng/ml (0.09–1.6 ng/ml) in women with
HbA1c less than median vs. 1.18 ng/ml (0.4–5.2 ng/ml) in
women with HbA1c more than median at 14 weeks GA, p=0.04).
There was no further difference in IGFI based on HbA1c ,/.
median at20 or 36 weeks gestation;there wasnodifference in growth
factor levels based on HbA1c ,/.median at other gestational ages.
A significant negative correlation was found between maternal
IGF-I and length of diabetes (r=20.621, p=0.01). There were no
other significant correlations between maternal or cord growth
factors and length of maternal diabetes.
Ultrasound markers (Diabetic group only)
Maternal PGH correlated significantly with EFW at both 33
(r=0.4, p=0.02) and 36 (r=0.42,p=0.03) weeks gestation, but
not at 30 weeks gestation (r=0.3, p=0.1). There were no other
significant correlations between EFW and any other growth factor,
nor was there a significant correlation between growth factors and
fetal abdominal circumference at any measured time points.
Maternal PGH correlated with fetal AAW at 33 weeks gestation
(r=0.48, p=0.019) but not at 30 weeks (r=0.1, p=0.6) or 36
weeks gestation (r=0.2, p=0.4).
Maternal PGH correlated with fetal BPD at 30 weeks (r=0.61,
p=0.02) and 33 weeks (r=0.45, p=0.03). There was no other
significant correlation between PGH and other skeletal markers or
with other growth factors and markers of skeletal growth. Of note,
fetal PGH did not correlate with fetal size or birth weight.
Clinical characteristics
There was no significant difference between maternal or fetal
growth factors regarding mode of delivery, gender of infant or
composite poorer perinatal outcome.
Table 2. Maternal and Fetal placental growth hormone, IGF-I, and IGFBP3 in non diabetic and Type 1 diabetic pregnancy.
Non-diabetic pregnancy (n=25) T1DM pregnancy (n=25) p value
Maternal PGH (ng/ml) 10639.4 (322.09–89,121.8) 9822.9 (1,293.2–86,679.6) 0.7
Fetal PGH (ng/ml) 164.72 (31–1796) 219.9 (10–1208) 0.5
Maternal IGF-I (ng/ml) 3.27 (0.74–11.17) 2.26 (0.3–8.18) 0.036
Fetal IGF-I (ng/ml) 1.17 (0.31–8.74) 0.76 (0.09–5.33) 0.18
Maternal IGFBP3(ng/ml) 25.95 (6.54–52.03) 47.1 (10.71–124.73) 0.001
Cord IGFBP3 (ng/ml) 10 (7–19.8) 14.95 (6.61–41.24) 0.001
Data presented as median (range). PGH placental growth hormone, IGF-I insulin like growth factor 1, IGFBP3 insulin like growth factor binding protein3 .
doi:10.1371/journal.pone.0029164.t002
Figure 2. Western immunoblot of IGFBP3 in maternal and fetal serum in non-diabetic (non-pregnant, first trimester, third trimester
and cord samples) and type 1 diabetes (first trimester, third trimester and cord samples).
doi:10.1371/journal.pone.0029164.g002
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Placentae in the diabetic group were the same weight as those of
non-diabetic controls (non diabetic 588 (452–705 g) vs. T1DM
580 g (398–755 g), p=0.9). Placental weight correlated to
maternal PGH only within the diabetic group (r=0.42, p=
0.43), there was no other significant correlation between placental
weight and maternal or fetal growth factors in either the non-
diabetic nor T1DM groups.
Western immunoblot analysis
Our ELISA data indicated that IGFBP3 levels were elevated in
type1diabeticmothers(Fig.1).IGFBP3 isinactivated byproteolysis
in vivo. To determine if changes in IGFBP3 detected by ELISA
were accompanied by increased IGFBP3 proteolysis, serum from
different patient groups were probed by Western blotting.
Comparison of control first versus third trimester indicated that
the levels of a 16 kDa proteolytic fragment of IGFBP3 decreased as
pregnancy progressed (Fig. 2). Interestingly, levels of this IGFBP3
fragment did not appear to decrease as much in diabetic patients in
the third versus first trimester compared to non-diabetic controls.
These data suggest that increased proteolysis of IGFBP3 may be a
feature of late-stage type diabetic pregnancy.
Discussion
This study is the first to report detectable PGH in fetal blood of
type 1 diabetic mothers. Maternal and fetal PGH levels were
found to be similar to those of non-diabetic controls. Although
there was no difference in crude birth weight measurements,
women with T!DM delivered at an earlier gestational age and the
birth weight centile (correcting birth weight for gestational age at
delivery) was higher in the T1DM group compared to the non-
diabetic group. Although fetal PGH did not correlate with fetal
growth, maternal PGH in the diabetic group was significantly
correlated with antenatal measurements of fetal adiposity and fetal
skeletal growth as well as to birth weight and birth weight centile.
IGF-I in maternal diabetic serum was lower than that of normal
controls. IGFBP3, a major regulator of IGF, was detected at
higher levels in diabetic maternal and fetal blood. Western blot
analysis of IGFBP3 suggests that the apparent increase in IGFBP3
levels in mothers with T1DM may be due to increased proteolysis
of IGFBP3, though the rise in IGFBP3 in fetal blood appears to be
genuine, since there was no apparent difference in fetal IGFBP-3
proteolysis as determined by western immunoblot analysis.
Placental Growth Hormone in fetal blood
Previously it was thought that PGH was only secreted into the
maternal circulation and was not detected in fetal blood [20]. The
initial studies investigating placental growth hormone used radio-
immunoassaywithmonoclonal antihuman GHantibodies[20],high
levels of pituitary GH were found in the fetal serum but no PGH.
Subsequent studies used a sensitive solid phase immuno-radiometric
assay whose lowest level of detection was 0.4 ng/ml. Recently a
study investigating PGH in pregnancies affected by pre-eclampsia
detected fetal PGH for the first time; the authors conclude this was
due to the use of an enzyme linked immunosorbent assay with a
lower limit of detection of 0.01 ng/ml which would not be affected
by th presence of GH binding protein (a potential confounder in
earlier studies) [21]. We have confirmed the presence of fetal PGH
and at levels similar to those previously reported.
A role for PGH in the fetus
PGH is secreted from the syncytiotrophoblast in a non-pulsatile
fashion [22]. It is traditionally believed that only substances with a
molecular weight less than 1 kDa can cross the placental barrier
[23]; as PGH has a molecular weight of 22 kDa it seems
reasonable to presume that PGH is secreted directly from the
syncytiotrophoblast into the fetal circulation. We have found PGH
at much lower levels (5%) compared to maternal PGH and
therefore its role in fetal growth is debatable. Given that maternal
PGH has high somatogenic activity [24], it is also reasonable to
presume that fetal PGH may have a similar role in the fetus. We
did not, however, find any association between fetal PGH and
either ultrasound markers or birth weight. PGH is also thought to
have a role in placental development and function [20]. We did
not find any association between fetal PGH levels and placental
weight or volume, though further more detailed investigations of
the functional role of fetal PGH are required to confirm this.
Finally, in addition to the PGH gene, a second gene (thought to
code for the yet to be defined Growth Hormone Variant 2, GHV1
being PGH) has been described [25] which may represent more
than 30% of the transcripts of the placental variants of growth
hormone. Therefore the fetal PGH detected may not represent all
placental growth hormone variants, the remainder of which may
have other, as yet undefined, roles.
Fetal Placental Growth Hormone in pathological
pregnancies
Our hypothesis was that fetal PGH would have an essential role
in diabetic fetal growth and would be detected in higher levels
than controls. While we have already discussed that the role of
fetal PGH in normal and diabetic pregnancies remains to be
defined, it is of interest that fetal PGH was similar in T1DM
pregnancies compared to controls. The only other study to date
detecting PGH in fetal blood investigated pregnancies affected by
pre-eclampsia, pre-eclampsia and infants delivered small for
gestational age (SGA) and pregnancies with SGA infants alone,
both compared to controls. Fetal PGH was significantly higher in
infants of women with pre-eclampsia. The researchers postulated
that maternal PGH was a compensatory mechanism to preserve
fetal growth and failure of this mechanism may result in a SGA
infant [21].
Maternal PGH in diabetic pregnancy
It is interesting that maternal PGH correlated with ultrasound-
derived estimates of fetal weight, fetal skeletal growth and with
fetal anterior abdominal wall thickness. These are new findings,
and suggest that maternal PGH is related to fetal size and not
necessarily just to fetal adiposity.
Glucose also has an affect on both PGH and IGF. The absence
of glucose has been shown to profoundly increase PGH in vitro
[26] as does low concentrations of glucose [27]. This effect of
glucose on PGH may be limited to pregnancies affected with
diabetes, as PGH has been shown to remain stable in glucose
challenge tests in non-diabetic human pregnancies [28]. Despite
this association, we did not find a relationship between PGH and
HbA1c; also free PGH does not correlate with maternal insulin
requirements [29]. Women with severe hypoglycaemia in
pregnancy (defined as five or more hypoglycaemic attacks) had
25% lower IGFI in pregnancy compared to women with T1DM
and few or no episodes of hypoglycaemia [30]. This finding is of
interest in the context of IGF1 being significantly lower in women
with a lower HbA1c in the first pregnancy, as we have shown in
this study.
Glycaemia itself has a significant effect on fetal weight: the
HAPO study showed a relationship between maternal glycaemia
and birth weight even in those without defined gestational
diabetes, and in diabetic pregnancies maternal glycaemia may
IGF Axis in Diabetic Pregnancy
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showed that even early HbA1c correlated with birth weight
centile, as well as third trimester HbA1c.
The third trimester of pregnancy is a time of relative insulin
resistance, when the carbohydrate metabolism of the mother is
altered so as to defer fuels to the growing demands of the growing
fetus [31]. This insulin resistance is mediated in part by placental
hormones, including placental growth hormone, human placental
lactogen, leptin and resistin [32]. Therefore as well as glycaemia
affecting PGH, it is reasonable to assume that PGH may have an
effect on glycaemia. We did not find any association between PGH
and maternal HbA1c or fructosamine (results not shown); had we
studied maternal insulin requirements or maternal serum glucose
different results may have been found but for pragmatic reasons
these investigations were not done.
Insulin like Growth Factor I
IGF production in the liver is stimulated by endogenous insulin.
In non-pregnant individuals with diabetes, IGF-I is lower in
diabetic serum compared to non-diabetic serum. This may be due
to a combination of factors, including hepatic GH resistance,
insufficient portal insulinisation, inadequate nutrition and exoge-
nous insulin administration bypassing the liver and thus not
stimulating IGF production [33]. We have shown that the length
of diabetes negatively correlates with level of maternal IGF-I,
suggesting that the differences outlined above become more
entrenched with increasing duration of diabetes. We also showed
that infants born to mothers with lower IGF-I levels were more
likely require admission to the NICU, though this may be
confounded by the maternal diabetic effect.
Insulin Like Growth Factor Binding Protein 3
We have shown that serum IGFBP3 levels increased in both
diabetic mothers and their infants. We hypothesized that this may
be artifactual due to increased IGFBP3 proteolysis. We investi-
gated this by performing Western immunoblot analysis of
IGFBP3. The appearance of a band at 16 kD suggests that there
is increased proteolysis in maternal serum in the third trimester. In
addition, this proteolysis appears to occur after the first trimester,
as no band at 16 kD was seen in the diabetic serum in early
pregnancy samples. To our knowledge this is the first time that
increased proteolysis of IGFBP3 has been shown in human
diabetic pregnancies. If the primary function of IGFBP3 is to bind
IGF-I and reduce its bioavailability, then increased proteolysis in
the third trimester may increase the level of IGF-I, perhaps in
order to stimulate growth during the period of maximum fetal
growth.
This band does not appear in fetal diabetic serum, suggesting
that the increase in fetal IGFBP3 diabetic mothers is a genuine
increase in total IGFBP3 rather than increased IGFBP3 fragments.
This is supported by other studies showing an increased fetal
IGFBP3 in diabetic pregnancy [34]. The higher IGFBP3 may thus
increase binding of IGF-I and reduce its bioavailability. This may
well be a component of the overall mechanism suppressing IGF-I
activity in fetal blood discussed above.
One limitation of the study was the number of participants
involved; as with any study a larger number may have changed the
results. Secondly, only PGH, IGFI and IGFBP3 were measured.
PGH and Pituitary GH share a common binding protein, GHBP,
which regulates the concentration of free –biologically active -
PGH in serum. GHBP has been shown to decrease with advancing
gestational age in T1DM, with a corresponding increase in free
PGH [11]. Free PGH increases in maternal serum in T1DM at 28
and 36 weeks gestation, with both total PGH and free PGH
correlating to fetal ponderal index (and thus adiposity). Free PGH,
IGFBP3, IGFBP1, IGF2 and GHBP may explain 40% of the
variance in birth weight. Therefore the exclusion of GHBP is a
limitation of this study. For pragmatic reasons we chose to study
PGH, IGF1 and IGFBP3 considering these the most relevant in
third trimester. In retrospect it may have been useful to assess total
PGH and GHBP as well as free PGH in fetal serum to see if these
measurements would have correlated to fetal growth.
These results suggest that in T1DM pregnancies, the maternal
and fetal PGH-IGF-I-IGFBP3 is altered, providing further
information why pregnancies of diabetic women are at increased
risk of fetal macrosomia.
Methods
Patient cohort
This was a prospective cohort study of patients attending the
hospital between 2005 and 2008. With institutional ethics
approval (National Maternity Hospital, Dublin, Ireland) and
informed written consent, women underwent routine antenatal
care, but in addition maternal blood was drawn at 36 weeks
gestation. Following delivery of the baby but before delivery of the
placenta, cord blood was obtained from the umbilical vein. Blood
was centrifuged and plasma stored at 220uC.
For the purpose of ease of sample collection the majority of cord
samples were obtained from women undergoing elective caesarean
section (CS), with the indication for delivery being either breech
presentation or elective repeat delivery in both groups. Women
with T1DM underwent earlier delivery than non-diabetic
pregnancies. The baseline CS rate in our unit is 18%.
Type 1 Diabetes was defined as a metabolic disease character-
ized by hyperglycaemia as a result of insulin deficiency. None of
the diabetic group had any medical problems other than diabetes.
Women who screened negative for gestational diabetes were
invited to participate as controls. In the Republic of Ireland
screening for gestational diabetes is based on risk factor assessment
rather than universal screening. Risk factors for gestational
diabetes include a family history in a first-degree relative of
diabetes, previous gestational diabetes, previous unexplained
macrosomia, persistent glycosuria, unexplained polyhydramnious
or maternal obesity, amongst others. Should a patient have any of
these risk factors, she underwent a glucose tolerance test. All
pregnancies resulted in the delivery of a single live infant.
Clinical data collection
Clinical data on both normal and T1DM pregnancies was
obtained prospectively from the labour ward database, ultrasound
department database and patient records. Participant demogra-
phy, delivery details and infant outcomes such as birth weight,
birth weight centile and Apgar scores were recorded. Poor
perinatal outcome was defined as any of the following: Apgar at
1 or 5 minutes less than 7, cord pH less than 7.2 or admission to
the NICU for indication other than hypoglycaemia. In addition
measurements of glycaemic control (HbA1c) at early pregnancy
(first visit), second trimester (14 and 20 weeks gestation) and third
trimester (36 weeks gestation) were recorded. The median ges-
tational age at first visit was 5 weeks (range 4–7 weeks). Gestation
was defined clinically as number of weeks since date of certain last
menstrual period or by ultrasound assessment if dates were
uncertain. Birth weight was weight following delivery as measured
by a paediatrician or midwife using standardised scales (Seca 1
Model 335, Vogel and Halke, Germany). The gestation and
gender appropriate centile was determined using the growth charts
(Child Growth Foundation, London 1996) used in this institution.
IGF Axis in Diabetic Pregnancy
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Women with T1DM underwent the routine third trimester
ultrasound assessment for fetal wellbeing and fetal growth at 30, 33
and 36 weeks’ gestation. At each examination fetal growth (as
measured by bi-parietal diameter, head circumference, abdominal
circumference and femur length), measurement of fetal anterior
abdominal wall thickness [5] fetal wellbeing (bio-physical profile)
and Doppler assessment (of the umbilical artery and middle
cerebral artery) was performed. Ultrasound measurements were
performed by one of three operators (MH, NR, FMcA). All
examinations were performed transabdominally using either a
Toshiba Xario (Toshiba Medical Systems Corporation, Japan) or
Voluson 730 Expert, (GE Medical Systems, Germany) equipped
with curved array transducers. Growth factors were correlated
with ultrasound markers including estimated fetal weight (EFW),
abdominal circumference (AC), and fetal anterior abdominal wall
thickness (AAW) (as measurements of fetal adiposity) as well as
femur length (FL) bi-parietal diameter (BPD) and head circum-
ference (HC) (markers of fetal skeletal growth).
Statistics
Statistical analysis was performed using SPSS version 16. Data
was assessed for normality using Shapiro Wilk and p-p plot;
normally distributed data was compared using t test (mean +/2
standard error). Proportions were compared using chi
2 test or
Fishers test as appropriate. P values,0.05 were considered
significant.
Experiment
ELISA analysis. Placental Growth Hormone was measured
by enzyme-linked immunoassay (Diagnostic Systems Laboratories,
Texas) with an intra-assay precision of 6.7% and inter-assay
precision of 6.4%. The minimal detectable level of hPGH is 8 pg/
ml in this assay. Samples reporting the maximum detectable levels
were repeated at diluted levels (62,610,620) until measurements
were within the linear range were recorded. Insulin Like Growth
Hormone I was measured by enzyme-linked immunoassay (R & D
Systems, Minneapolis) with an intra-assay precision of 4.3% and
inter-assay precision of 7.5%. The minimal detectable level of
IGF-I is 0.026 ng/ml in this assay. Insulin Like Growth Factor
Binding Protein 3 (IGFBP3) was measured by enzyme-linked
immunoassay (R & D Systems, Minneapolis) with an intra-assay
precision of 4.1% and inter-assay precision of 6.9%. The minimal
detectable level of IGFBP3 is 0.05 ng/ml in this assay. Samples
were analysed on a Molecular Devices multiwell plate reader at
450 nm. Readings were normalised using a standard curve and
concentrations extrapolated and analysed.
Western Blot. For the western blot analysis, seven groups
were analysed: non pregnant non diabetic controls, first trimester
non-diabetic controls, first trimester T1DM, third trimester non-
diabetic controls, third trimester T1DM and cord samples from
infants of the non-diabetic and T1DM third trimester participants.
Fetal and maternal serum samples were obtained from the same
consenting participants as previously described. 50 microlitres of
serum from five patients per indicated group were separated by
10% (w/v) SDS-PAGE and transferred to PVDF membrane using
standard techniques. Membranes were blocked with 3% (w/v)
milk solution and incubated overnight with IGFBP3 primary
antibody (1:1000 dilution, Santa Cruz, sc-6004). Membranes were
washed with TBS-Tween and incubcated with 1:10,000 anti-
rabbit HRP for 60 min. Membranes were incubated with ECL
reagents and immunoreactive bands visualised with X-ray film.
Author Contributions
Conceived and designed the experiments: DPB PAC FMM. Performed the
experiments: MFH KCN. Analyzed the data: MFH FMM. Contributed
reagents/materials/analysis tools: FMM. Wrote the paper: MFH NER
PAC DPB FMM.
References
1. Confidential Enquiry into Maternal And Child Health (2005) Pregnancy in
women with Type 1 and Type 2 Diabetes in 2002–03. England, Wales and
Northern Ireland, CEMACH London.
2. Corrigan N, Brazil DP, McAuliffe F (2009) Fetal cardiac effects of maternal
hyperglycemia during pregnancy. Birth Defects Res A Clin Mol Teratol 85(6):
523–30.
3. Russell NE, Foley M, Kinsley BT, Firth RG, Coffey M, et al. (2008) Effect of
pregestational diabetes mellitus on fetal cardiac function and structure.
American Journal of Obstetrics & Gynecology 199: 312.e1–7.
4. Langer O (2000) Fetal macrosomia: etiologic factors. Clin Obstet Gynecol 43:
283–97.
5. Higgins M, Russell N, Mulcahy C, Coffey M, Foley ME, et al. (2008) Fetal
Anterior Abdominal Wall Thickness in Diabetic Pregnancy. Eur J Obstet
Gynecol 140(1): 43–7.
6. Diabetes Control and Complications Trial Research Group (1996) Pregnancy
outcomes in the Diabetes Control and Complications Trial. Am J Obstet
Gynecol 174: 1343–53.
7. Baird J, Fisher D, Lucas P, Kleijner J, Roberts H, et al. (2005) Being big or
growing fast: systematic review of size and growth in infancy and later obesity.
BMJ 331(7522): 929.
8. Berk M, Mimouni F, Miodovnik M, et al. (1989) Macrosomia in infants of
insulin-dependent diabetic mothers. Pediatrics 86: 1029–34.
9. Higgins M, McAuliffe F (2010) A Review of Maternal and Fetal Growth Factors
in Diabetic Pregnancy. Curr Diabetes Rev 6(2): 116–25.
10. Kliman HJ, Nestler JE, Sermasi E, Sanger JM, Strauss JF (1986) Purification,
characterization, and in vitro differentiation of cytotrophoblasts from human
term placentae. Endocrinology 118: 1567–82.
11. Fuglsang J, Lauszus F, Flyvbjerg A, Ovesen P (2003) Human placental growth
hormone, insulin-like growth factor I and -II, and insulin requirements during
pregnancy in type 1 diabetes. J Clin Endocrinol Metab 88: 4355–61.
12. Mirlesse V, Frankenne F, Alsat E, Poncelet M, Hennen G, et al. (1993) Placental
growth hormone levels in normal pregnancy and in pregnancies with
intrauterine growth retardation. Pediatr Res 34: 439–42.
13. McIntyre HD, Serek R, Crane DI, Veveris-lowe T, Parry A, et al. (2000)
Placental growth hormone (GH), GH-binding protein, and insulin-like growth
factor axis in normal, growth-retarded, and diabetic pregnancies: correlations
with fetal growth. J Clin Endocrinol Metab 85: 1143–50.
14. Hu L, Lytras A, Bock ME, Yuen CK, Dodd JG, et al. (1999) Detection of
placental growth hormone variant and chorionic somatomammotropin-L RNA
expression in normal and diabetic pregnancy by reverse transcriptase-
polymerase chain reaction. Mol Cell Endocrinol 157: 131–42.
15. Sara VR, Hall K (1990) Insulin-like growth factors and their binding proteins.
Physiol Rev 70: 591–614.
16. Whittaker PG, Stewart MO, Taylor A, Howell RJ, Lind T (1990) Insulin growth
factor 1 and its binding protein 1 during normal and diabetic pregnancies.
Obstet Gynecol 76(2): 223–9.
17. Yan-Jun L, Tsushima T, Minei S, Sanaka M, Nagashima T, et al. (1996) Insulin-
like growth factors (IGFs) and IGF-binding proteins (IGFBP-1, -2 and -3) in
diabetic pregnancy: relationship to macrosomia. Endocr J 43: 221–31.
18. Holmes RP, Holly JM, Soothill PW (1999) Maternal serum insulin-like growth
factor binding protein-2 and -3 and fetal growth. Hum Reprod 14: 1879–84.
19. Guler HP, Zapf J, Schmid C, Froesch ER (1989) Insulin-like growth factors I
and II in healthy man. Estimations of half-lives and production rates. Acta
Endocrinol (Copenh) 121: 753–8.
20. Frankenne F, Closset, Gomez F, Scippo ML, Smal J, et al. (1988) The hysiology
of growth hormones (GHs) in pregnant women and partial characterization of
the placental GH variant. Journal of Clinical Endocrinology & Metabolism 66:
1171–80.
21. Mittal P, Espinoza J, Hassan S, Kusanovic JP, Edwin SS, et al. (2007) Placental
growth hormone is increased in the maternal and fetal serum of patients with
preeclampsia. J Matern Fetal Neonatal Med 20: 651–9.
22. Eriksson T, Voog L, Walinder J, Eriksson TE (1989) Diurnal rhythm in absolute
and relative concentrations of large neutral amino acids in human etplasma.
Journal of Psychiatric Research 23: 241–9.
23. DiPiro J, Talbert R, Yee G, Matzke G, Wells B, et al. (1989) Gynaecologic
Disorders. Pharmacotherapy 7 ed., Mc Graw Medical.
24. Selden RF, Wagner TE, Blethen S, Yun JS, Rowe ME, et al. (1988) Expression
of the human growth hormone variant gene in cultured fibroblasts and
transgenic mice. Proceedings of the National Academy of Sciences of the United
States of America 85: 8241–5.
IGF Axis in Diabetic Pregnancy
PLoS ONE | www.plosone.org 7 February 2012 | Volume 7 | Issue 2 | e2916425. Alsat E, Guibourdenche J, Couturier A, Evain-Brion D (1998) Physiological role
of human placental growth hormone. Mol Cell Endocrinol 140: 121–7.
26. Fuglsang J, Moller N, Ledet T, Ovesen P (2008) Effects of glucose, glycerol, 3
hydroxybuterate , insulin and leptin on PGH secretion in placental explants.
Horm Metab Res 40(3): 189–93.
27. Bjorklund AO, Adamson UK, Carlstrom KA, Kennen G, Igout A, et al. (1998)
Placental hormones during induced hypoglycaemia in pregnant women with
insulin dependent diabetes mellitus: evidence of an active role for placenta in
hormonal counter regulation. BJOG 105(6): 649–55.
28. Mcintyre HD, Russell A, Serek R, Veveis-Lowe T, Cotterrill A, et al. (2002)
Placental growth Hormone is not suppressed by oral glucose loading in normal
human pregnancy. Horm Metab Res 34(5): 250–3.
29. Fuglsang J, Lauszus FF, Fisker S, Flyvbjerg A, Ovesen P (2005) Growth
hormone binding protein and maternal body mass index in relation to placental
growth hormone and insulin requirements during pregnancy in type 1 diabetic
women. Growth Horm IGF Res 205: 15(3): 223–30.
30. Ringholm Nielsen L, Juul A, Pedersen-Bjergaard U, Thorsteinsson B, Samm P,
et al. (2008) Lower levels of circulating IGFI in T1DM women with frequent
severe hypoglycaemia in pregnancy. Diabetes Med 25(7): 826–33.
31. Yamashita H, Shao J, Friedman JE (2000) Physiologic and molecular alterations
in carbohydrate metabolism during pregnancy and gestational diabetes. Clin
Obstet Gynecol 43: 87–98.
32. Barbour LA, Shao J, Qiao L, Leitner W, Anderson M (2004) Human Placental
Growth Hormone increases expression of the p85 regulatory unit of
phosphatidylinositol 3 kinase and triggers severe insulin resistance in skeletal
muscle. Endocrinology 145(3): 1144–50.
33. Cooke NE, Ray J, Watson MA, Estes PA, Kuo BA, et al. (1988) Human growth
hormone gene and the highly homologous growth hormone variant gene display
different splicing patterns. Journal of Clinical Investigation 82: 270–5.
34. Tan K, Baxter R (1986) Serum IGF1 levels in adult diabetic patients: the effect
of age. J Clin Endo Metab 63: 651–5.
IGF Axis in Diabetic Pregnancy
PLoS ONE | www.plosone.org 8 February 2012 | Volume 7 | Issue 2 | e29164